Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) - Net Assets
Based on the latest financial reports, Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) has net assets worth CN¥1.05 Billion CNY (≈ $154.23 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.98 Billion ≈ $289.93 Million USD) and total liabilities (CN¥927.34 Million ≈ $135.70 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset allocation strategy of Zhuhai Rundu Pharmaceutical Co Ltd Class to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.05 Billion |
| % of Total Assets | 53.2% |
| Annual Growth Rate | 14.02% |
| 5-Year Change | -6.63% |
| 10-Year Change | 160.78% |
| Growth Volatility | 20.09 |
Zhuhai Rundu Pharmaceutical Co Ltd Class A - Net Assets Trend (2011–2025)
This chart illustrates how Zhuhai Rundu Pharmaceutical Co Ltd Class A's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see Zhuhai Rundu Pharmaceutical Co Ltd Class market cap and net worth.
Annual Net Assets for Zhuhai Rundu Pharmaceutical Co Ltd Class A (2011–2025)
The table below shows the annual net assets of Zhuhai Rundu Pharmaceutical Co Ltd Class A from 2011 to 2025. Also explore 002923 shareholders equity momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.04 Billion ≈ $151.95 Million |
-9.87% |
| 2024-12-31 | CN¥1.15 Billion ≈ $168.59 Million |
-2.29% |
| 2023-12-31 | CN¥1.18 Billion ≈ $172.55 Million |
-1.41% |
| 2022-12-31 | CN¥1.20 Billion ≈ $175.01 Million |
+7.54% |
| 2021-12-31 | CN¥1.11 Billion ≈ $162.74 Million |
+7.12% |
| 2020-12-31 | CN¥1.04 Billion ≈ $151.93 Million |
+10.42% |
| 2019-12-31 | CN¥940.29 Million ≈ $137.59 Million |
+7.92% |
| 2018-12-31 | CN¥871.29 Million ≈ $127.50 Million |
+78.24% |
| 2017-12-31 | CN¥488.84 Million ≈ $71.53 Million |
+22.77% |
| 2016-12-31 | CN¥398.19 Million ≈ $58.27 Million |
+28.15% |
| 2015-12-31 | CN¥310.72 Million ≈ $45.47 Million |
+13.69% |
| 2014-12-31 | CN¥273.31 Million ≈ $39.99 Million |
+15.67% |
| 2013-12-31 | CN¥236.29 Million ≈ $34.58 Million |
+18.48% |
| 2012-12-31 | CN¥199.43 Million ≈ $29.18 Million |
+20.62% |
| 2011-12-31 | CN¥165.33 Million ≈ $24.19 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Zhuhai Rundu Pharmaceutical Co Ltd Class A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 569.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥374.76 Million | 36.09% |
| Other Components | CN¥663.64 Million | 63.91% |
| Total Equity | CN¥1.04 Billion | 100.00% |
Zhuhai Rundu Pharmaceutical Co Ltd Class A Competitors by Market Cap
The table below lists competitors of Zhuhai Rundu Pharmaceutical Co Ltd Class A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Sella Real Estate
TA:SLARL
|
$535.61 Million |
|
Bank Maspion Indonesia PT
JK:BMAS
|
$535.68 Million |
|
ZimVie Inc
NASDAQ:ZIMV
|
$535.72 Million |
|
Esso S.A.F.
PA:ES
|
$535.78 Million |
|
Chenming Mold Industrial Corp
TW:3013
|
$535.14 Million |
|
Rural Funds Group
AU:RFF
|
$534.96 Million |
|
Hangzhou Dadi Haiyang Environmental Protection Co. Ltd.
SHE:301068
|
$534.55 Million |
|
Smartoptics Group AS
OL:SMOP
|
$534.43 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Zhuhai Rundu Pharmaceutical Co Ltd Class A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,152,106,763 to 1,038,399,560, a change of -113,707,203 (-9.9%).
- Net loss of 63,472,074 reduced equity.
- Dividend payments of 64,089,730 reduced retained earnings.
- Other comprehensive income decreased equity by 140,902,790.
- Other factors increased equity by 154,757,390.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-63.47 Million | -6.11% |
| Dividends Paid | CN¥64.09 Million | -6.17% |
| Other Comprehensive Income | CN¥-140.90 Million | -13.57% |
| Other Changes | CN¥154.76 Million | +14.9% |
| Total Change | CN¥- | -9.87% |
Book Value vs Market Value Analysis
This analysis compares Zhuhai Rundu Pharmaceutical Co Ltd Class A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.52x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 16.21x to 3.52x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2011-12-31 | CN¥0.67 | CN¥10.92 | x |
| 2012-12-31 | CN¥0.81 | CN¥10.92 | x |
| 2013-12-31 | CN¥0.96 | CN¥10.92 | x |
| 2014-12-31 | CN¥1.11 | CN¥10.92 | x |
| 2015-12-31 | CN¥1.27 | CN¥10.92 | x |
| 2016-12-31 | CN¥1.63 | CN¥10.92 | x |
| 2017-12-31 | CN¥2.00 | CN¥10.92 | x |
| 2018-12-31 | CN¥2.64 | CN¥10.92 | x |
| 2019-12-31 | CN¥2.78 | CN¥10.92 | x |
| 2020-12-31 | CN¥3.11 | CN¥10.92 | x |
| 2021-12-31 | CN¥3.30 | CN¥10.92 | x |
| 2022-12-31 | CN¥3.54 | CN¥10.92 | x |
| 2023-12-31 | CN¥3.53 | CN¥10.92 | x |
| 2024-12-31 | CN¥3.47 | CN¥10.92 | x |
| 2025-12-31 | CN¥3.10 | CN¥10.92 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Zhuhai Rundu Pharmaceutical Co Ltd Class A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -6.11%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -5.40%
- • Asset Turnover: 0.58x
- • Equity Multiplier: 1.95x
- Recent ROE (-6.11%) is below the historical average (14.98%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 19.48% | 10.35% | 1.30x | 1.44x | CN¥15.68 Million |
| 2012 | 28.38% | 15.64% | 1.23x | 1.47x | CN¥36.65 Million |
| 2013 | 25.12% | 13.67% | 1.26x | 1.46x | CN¥35.73 Million |
| 2014 | 21.78% | 11.37% | 1.39x | 1.37x | CN¥32.19 Million |
| 2015 | 22.90% | 12.31% | 1.16x | 1.61x | CN¥40.09 Million |
| 2016 | 21.97% | 13.42% | 1.06x | 1.55x | CN¥47.65 Million |
| 2017 | 18.54% | 11.63% | 1.10x | 1.44x | CN¥41.77 Million |
| 2018 | 12.26% | 10.24% | 0.92x | 1.31x | CN¥19.71 Million |
| 2019 | 12.64% | 8.74% | 1.03x | 1.41x | CN¥24.87 Million |
| 2020 | 13.09% | 10.85% | 0.83x | 1.46x | CN¥32.04 Million |
| 2021 | 12.57% | 11.75% | 0.62x | 1.72x | CN¥28.55 Million |
| 2022 | 13.00% | 11.33% | 0.60x | 1.91x | CN¥35.88 Million |
| 2023 | 5.67% | 5.18% | 0.58x | 1.89x | CN¥-51.02 Million |
| 2024 | 3.46% | 3.37% | 0.54x | 1.90x | CN¥-75.33 Million |
| 2025 | -6.11% | -5.40% | 0.58x | 1.95x | CN¥-167.31 Million |
Industry Comparison
This section compares Zhuhai Rundu Pharmaceutical Co Ltd Class A's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $8,448,219,723
- Average return on equity (ROE) among peers: 10.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Zhuhai Rundu Pharmaceutical Co Ltd Class A (002923) | CN¥1.05 Billion | 19.48% | 0.88x | $535.14 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.14 Billion | 22.15% | 4.96x | $585.22 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.15 Billion | 3.98% | 1.16x | $407.31 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $897.61 Million | 10.79% | 0.14x | $4.27 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $14.94 Billion | 12.78% | 0.66x | $2.26 Billion |
| Wedge Industrial Co Ltd (000534) | $552.92 Million | 0.39% | 0.01x | $1.78 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $38.10 Billion | 10.98% | 0.30x | $13.33 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.63 Billion | 2.92% | 0.71x | $875.19 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $311.17 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $2.05 Billion | 23.18% | 1.96x | $973.03 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $18.87 Billion | 8.83% | 0.08x | $3.07 Billion |
About Zhuhai Rundu Pharmaceutical Co Ltd Class A
Zhuhai Rundu Pharmaceutical Co., Ltd. engages in the research and development, production, and sale of chemical pharmaceutical preparations, APIs, and pharmaceutical intermediates in China and internationally. It offers FDF for cardiovascular, gastrointestinal, antibiotics, analgetic and antipyretics, anti-virus, endocrinology, and respiratory; and pellets for excipient, antiulcerative, diabetes … Read more